Halozyme Therapeutics, Inc. has just announced a significant increase in its revenue estimates for 2025 and provided updated financial guidance for 2026. The company's preliminary unaudited 2025 estimates show a total revenue of $1,385 * $1,400 million, representing a year-over-year (yoy) growth of 36% to 38%. Additionally, royalty revenue for 2025 is estimated to be $865 * $870 million, with a yoy growth of 51% to 52%.
Looking ahead, Halozyme has raised its 2026 financial guidance. The company now expects total revenue for 2026 to be in the range of $1,710 * $1,810 million, reflecting a yoy growth of 23% to 30%. Royalty revenue for 2026 is projected to be $1,130 * $1,170 million, with a yoy growth of 30% to 35%. Adjusted EBITDA has also been increased to $1,125 * $1,205 million, and non-GAAP diluted EPS is expected to be in the range of $7.75 * $8.25.
Halozyme's recent acquisition of Surf Bio, Inc. for an upfront payment of $300 million, with the potential for up to $100 million in milestone payments, has expanded its drug delivery opportunity. Surf Bio's hyperconcentration technology aims to enable high concentrations of up to 500 mg/ml across a wide range of therapeutics, including monoclonal antibodies and small molecules, for delivery in a single auto-injector shot for at-home or in-hcp office use.
Dr. Helen Torley, President and CEO of Halozyme, emphasized the strength of the company's core enhanze business and the exceptional momentum built in 2025, with royalty revenue growth expected to exceed 50% yoy. She also highlighted the strategic growth roadmap, including the acquisitions of Elektrofi and Surf Bio, which broaden the drug delivery portfolio and opportunity, extend royalty horizons, and diversify pathways to create value.
The increased multi-year guidance reflects confidence in delivering durable revenue growth well into the 2040s and supports the company's long-term growth profile, aiming to deliver sustained value for shareholders. With the acquisition of Surf Bio and its hyperconcentration technology, Halozyme is poised to further transform the patient treatment experience and expand the scope of therapeutics that can be delivered subcutaneously.
Following these announcements, the company's shares moved -0.85%, and are now trading at a price of $71.21. If you want to know more, read the company's complete 8-K report here.
